The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations

Blood Cancer Journal

Volumn 1, Issue 4, 2011, Pages

  Mishima, Y ^a   Terui, Y ^a   Takeuchi, K ^b   Matsumoto Mishima, Y ^a   Matsusaka, S ^a   Utsubo Kuniyoshi, R ^a   Hatake, K ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

Antibody therapy; B cell lymphomas; CD20; Mutations; Rituximab

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; L26 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING SITE; BIOTRANSFORMATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CRYOPRESERVATION; CYTOPLASM; DRUG ANTIGENICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE IDENTIFICATION; GENE MUTATION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PLEURA EFFUSION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; STOP CODON; TREATMENT RESPONSE; WESTERN BLOTTING; WILD TYPE;

EID: 84863963373     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.11     Document Type: Article

References (19)

1. Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Kuniyoshi R et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res 2009; 15: 2523-2530.
2. Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, van Dongen JJ. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990; 136: 1215-1222. (Pubitemid 20210319)
3. Norton AJ, Isaacson PG. Monoclonal antibody L26: an antibody that is reactive with normal and neoplastic B lymphocytes in routinely fixed and paraffin wax embedded tissues. J Clin Pathol 1987; 40: 1405-1412. (Pubitemid 18026321)
4. Hata H, Matsuzaki H, Matsuno F, Sonoki T, Takemoto S, Kuribayashi N et al. Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1. Clin Exp Immunol 1994; 96: 370-375. (Pubitemid 24213850)
5. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
6. Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S et al. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. Clin Cancer Res 2009; 15: 3624-3632.
7. Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem 2008; 283: 18545-18552.
8. Johnson NA, Leach S, Woolcock B, deLeeuw RJ, Bashashati A, Sehn LH et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica 2009; 94: 423-427.
9. Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009; 183: 749-758.
10. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111: 5486-5495.
11. Patz M, Isaeva P, Forcob N, Muller B, Frenzel LP, Wendtner CM et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011; 152: 295-306.
12. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393-4402.
13. Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007; 21: 2240-2245. (Pubitemid 350011695)
14. DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004; 10: 8620-8629. (Pubitemid 40053430)
15. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
16. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 2895-2899.
17. Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003; 22: 7389-7395. (Pubitemid 37487164)
18. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125. (Pubitemid 41039112)
19. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10: 25-38.